HC Wainwright & Co. Reiterates Buy on Relay Therapeutics, Maintains $20 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Relay Therapeutics (NASDAQ:RLAY) and maintained a price target of $20.
June 07, 2024 | 10:57 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Relay Therapeutics and maintained a price target of $20, indicating continued confidence in the company's potential.
The reiteration of a Buy rating and maintenance of a $20 price target by HC Wainwright & Co. suggests strong confidence in Relay Therapeutics' future performance. This positive analyst rating is likely to boost investor sentiment and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100